Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.57 | -$0.47 | -$0.52 |
Q2 2024 | 1 | -$0.63 | -$0.51 | -$0.57 |
Q3 2024 | 1 | -$0.48 | -$0.39 | -$0.43 |
Q4 2024 | 1 | -$0.38 | -$0.31 | -$0.34 |
Q1 2025 | 1 | -$0.29 | -$0.23 | -$0.26 |
Q2 2025 | 1 | -$0.22 | -$0.18 | -$0.20 |
Q3 2025 | 1 | -$0.22 | -$0.18 | -$0.20 |
Q4 2025 | 1 | -$0.23 | -$0.19 | -$0.21 |
Q1 2026 | 0 | $0.00 | $0.00 | $0.00 |
Q2 2026 | 0 | $0.00 | $0.00 | $0.00 |
Q3 2026 | 0 | $0.00 | $0.00 | $0.00 |
Q4 2026 | 0 | $0.00 | $0.00 | $0.00 |
Q1 2027 | 0 | $0.00 | $0.00 | $0.00 |
Q2 2027 | 0 | $0.00 | $0.00 | $0.00 |
Q3 2027 | 0 | $0.00 | $0.00 | $0.00 |
Q4 2027 | 0 | $0.00 | $0.00 | $0.00 |
BioRestorative Therapies, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.13 earnings per share for the quarter, topping analysts' consensus estimates of $-0.35 by $0.22. The company had revenue of 233,600 for the quarter and had revenue of 145,800 for the year. BioRestorative Therapies, Inc. has generated $-2 earnings per share over the last year ($-2.47 diluted earnings per share) and currently has a price-to-earnings ratio of -2.04. BioRestorative Therapies, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | -$0.35 | -$0.13 | 0.22 | $333,333 | $233,600 |
08/13/2024 | Q2 2024 | -$0.56 | -$0.50 | 0.06 | $10,000 | $89,100 |
06/11/2024 | Q1 2024 | -$0.51 | -$0.33 | 0.18 | $35,000 | |
06/11/2024 | Q4 2023 | -$0.51 | $0.25 | 0.76 | $19,300 | |
11/13/2023 | Q3 2023 | -$0.68 | -$0.02 | 0.66 | $30,000 | $30,700 |
08/11/2023 | Q2 2023 | -$1.56 | -$0.77 | 0.79 | $65,000 | $64,500 |
05/12/2023 | Q1 2023 | -$1.26 | -$1.51 | -0.25 | $31,300 | |
03/24/2023 | Q4 2022 | -$1.04 | $3,700 | |||
11/14/2022 | Q3 2022 | -$0.49 | -$1.29 | -0.8 | $29,000 | |
08/15/2022 | Q2 2022 | -$0.55 | -$1.30 | -0.75 | $71,100 | |
05/13/2022 | Q1 2022 | -$1.30 | $16,000 | |||
03/30/2022 | Q4 2021 | -$0.54 | -$23.39 | -22.85 | $5,000 | |
11/15/2021 | Q3 2021 | -$4.99 | $8,000 | $8,000 | ||
08/16/2021 | Q2 2021 | -$5.10 | $15,000 | |||
05/17/2021 | Q1 2021 | -$19.72 | $18,000 | |||
04/29/2021 | Q4 2020 | -$7.26 | $17,000 | |||
04/12/2021 | Q3 2020 | -$2.10 | $15,000 | |||
04/12/2021 | Q2 2020 | $7.21 | $19,000 | |||
03/29/2021 | Q1 2020 | -$18.94 | $26,000 | |||
03/17/2021 | Q4 2019 | -$3.89 | $32,000 |
BioRestorative Therapies, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, BioRestorative Therapies, Inc. (:BRTX) reported $-0.13 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.35 by $0.22.
The conference call for BioRestorative Therapies, Inc.'s latest earnings report can be listened to online.
The conference call transcript for BioRestorative Therapies, Inc.'s latest earnings report can be read online.
BioRestorative Therapies, Inc. (:BRTX) has a recorded annual revenue of $145,800.
BioRestorative Therapies, Inc. (:BRTX) has a recorded net income of $145,800. BioRestorative Therapies, Inc. has generated $-2.47 earnings per share over the last four quarters.
BioRestorative Therapies, Inc. (:BRTX) has a price-to-earnings ratio of -2.04 and price/earnings-to-growth ratio is 0.11.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED